Kalaris news
Kalaris Therapeutics, Inc. (Nasdaq: KLRS) (“Kalaris”), a clinical-stage biopharmaceutical company dedicated to the development and commercialization of treatments for prevalent retinal diseases, today announced the appointment of Leone Patterson to its Board of Directors and as Chair of the Board’s Audit Committee.
“We’re delighted to welcome Leone as Chair of the Board’s Audit Committee,” said David Hallal, Chairman of the
- Phase 2 study completed enrollment ahead of schedule
- Posoleucel well-tolerated with no cases of graft rejection observed to date
- Overall decline in median BK viral load among patients completing 12 weeks of dosing with posoleucel or placebo (2:1 randomization)
- Posoleucel detected up to 12 weeks after last infusion
- Topline, unblinded study results from all 61 patients expected to be released in 1Q 2023<
- Initiated posoleucel registrational study to prevent six devastating viral infections and now enrolling high-risk allo-HCT patients in the U.S., Western Europe and Asia
- FDA granted RMAT designation to posoleucel for Phase 3 multi-virus prevention indication with an estimated annual addressable patient population of 40,000 allo-HCT patients
- Progressed enrollment in three Phase 3 studies for posoleucel and a Phase 2 trial for
AlloVir (Nasdaq: ALVR), a late clinical-stage allogeneic T cell immunotherapy company, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to its lead investigational multi-virus-specific T cell therapy, posoleucel, for the prevention of clinically significant infections and disease from six devastating viruses that commonly impact high-risk adult and pediat
AlloVir (Nasdaq: ALVR), a late-clinical stage allogeneic T-cell immunotherapy company, today announced the appointment of Shawn Tomasello to its Board of Directors. Ms. Tomasello brings more than 35 years of broad experience building and leading commercial organizations in the life sciences industry, with specific expertise in cell and gene therapy.
“We’re thrilled to welcome Shawn to